Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP) —a structured summary of a study protocol for a randomized controlled study

DiscussionCombining behavioural counselling and medical therapy, e.g. with varenicline, improves abstinence rates and is considered the standard of care. We expect a further increase in quit rates by adding a second component of medical therapy and assume a dual effect of dulaglutide treatment (blunting nicotine withdrawal symptomsand reducing post-cessational weight gain). This project is of high relevance as it explores novel treatment options aimed at preventing the disastrous consequences of nicotine consumption and obesity.Trial registrationClinicalTrials.govNCT03204396. Registered on June 26, 2017.
Source: Trials - Category: Research Source Type: clinical trials